Research compound supplied in Australia by Pulse Biolabs for laboratory use. Available in 5mg.
Hexarelin was made to trigger growth hormone release. In animal hearts it kept doing things after that release was switched off, which is why it now has a second research identity.
Hexarelin is a six-amino-acid synthetic peptide that triggers growth hormone release through the ghrelin receptor on the pituitary, and separately binds CD36, a receptor on heart and blood-vessel cells. Human studies from the 1990s measured its hormone-release profile in healthy adults, including cortisol and prolactin rises and a declining response with repeated dosing; acute heart-function effects were measured in bypass-surgery patients, and longer-term cardiac work is in rats. It has no regulatory approval.
Read the full research note →| Presentation | Code | Status | Price |
|---|---|---|---|
| 5mg | HX5 | In stock | $80 |
No batch-specific test report is currently published for this product. What a report does and does not show.
Supplied as lyophilised (freeze-dried) powder in a sealed vial. Store sealed and protected from light at the conditions stated on the product label or supplied specification. Solvent choice, concentration and handling after reconstitution depend on the compound and on the laboratory’s own procedures, and are not specified here.
Hexarelin is not an approved medicine in Australia, and no approval elsewhere was identified. Growth hormone secretagogues are prohibited at all times in sport under WADA category S2.
Status checked 2026-09-23. Details and sources in the research note.